View a Transcript of the Podcast here

Next-Generation Screening Platforms: BBB Organoids and Beyond

Choi-Fong Cho, PhD, Instructor, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School

Dr. Choi-Fong Cho of Harvard Medical School spoke to CHI to discuss her breakthrough research and the development of BBB organoids to be used as a next-generation screening model for brain-penetrating molecules. She discusses next steps in her research, including investigating new compounds and drugs with this platform, as well as the potential to unlock new mechanisms and pathways.

View a Transcript of the Podcast here

Need for Translational Methods in CNS Drug Discovery

Antti Nurmi, Ph.D., Managing Director, Discovery, Charles River

Charles River offers early discovery phase efficacy testing for novel therapies aimed at neurological and psychiatric conditions. Using a full range of different animal models, we use translational methods including in vitro assays, behavioral and cognitive testing and imaging to accelerate the development of novel CNS and neurological disease related therapies. Multi-modal study designs are essential for robust preclinical data that translate to success in the clinic.

View a Transcript of the Podcast here

Next-Generation Human Body-on-a-Chip Systems for Toxicology, Drug Discovery, and Basic Biology Research

James J. Hickman, Ph.D., Professor, Nanoscience Technology, Chemistry, Biomolecular Science, and Electrical Engineering, University of Central Florida

Cambridge Healthtech Institute interviews Dr. James Hickman, Professor of Nanoscience Technology, Chemistry, Biomolecular Science, and Electrical Engineering at the University of Central Florida regarding developing next-generation human body-on-a-chip systems to impact early drug discovery and basic research.

View a Transcript of the Podcast here

Cancer Therapeutics – Advice for the Future

Aidan Synnott, Ph.D., Executive Director, Discovery Oncology, Charles River Laboratories

Aidan Synnott of Charles River Laboratories speaks to CHI on May 3, 2017. Charles River Laboratories will be speaking during the Preclinical Models and Tools in Oncology - Part 1 and Tumor Models for Cancer Immunotherapy - Part 2, June 13-15,2017 in Boston, MA.

View a Transcript of the Podcast here

Developing Microfluidics for Screening Drugs, Validating Compounds and Understanding Immune Response

Mohammad F. Kiani, Ph.D., FAHA, Professor, Mechanical Engineering, Bioengineering, and Radiation Oncology, Temple University

Mohammad F. Kiani of Temple University speaks to Cambridge Healthtech Institute on March 9, 2017. He will be a presenter during the 3D Cellular Models conference at World Preclinical Congress, June 12-16 in Boston, Massachusetts.

View a Transcript of the Podcast here

Immunosequencing for Cancer Immunotherapy Development

Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies

CHI interviewed Dr. Catherine Sanders, Director and Team Lead of Scientific Liaisons at Adaptive Biotechnologies on the utilization of high-throughput sequencing and expert bioinformatics profiling T-cell and B-cell receptors, also known as immunosequencing, to enable the development of a new generation of cancer immunotherapies.

View a Transcript of the Podcast here

Microfluidic 3D Cell Cultures and Organ Models for Drug Testing

Jeffrey T. Borenstein, Ph.D., Laboratory Technical Staff, Biomedical Microsystems, Draper Laboratory

Jeffrey Borenstein of Draper Laboratory speaks to Cambridge Healthtech Institute on May 9, 2016. Dr. Borenstein will present during the 3D Cellular Models meeting, part of the World Preclinical Congress, June 14-17 in Boston, Massachusetts.

View a Transcript of the Podcast here

A Conversation on Modern Lead Generation Strategies

Joerg Holenz, Ph.D., Director, Discovery and Preclinical Sciences; Project Leader, Neuroscience iMed, AstraZeneca Neuroscience

Joerg Holenz of AstraZeneca previews his in-depth course on Modern Lead Generation Strategies and highlights the important issues on this subject. Joerg will be speaking during the Mastering Medicinal Chemistry meeting, June 15-16, in Boston, MA.

View a Transcript of the Podcast here

Challenges and Future Directions of Blood-Brain Barrier Research

Robert D. Bell, Ph. D., Principal Scientist, Integrative Neuroscience, Pfizer

Dr. Robert D. Bell, Principal Scientist, Integrative Neuroscience at Pfizer spoke to CHI to discuss challenges in in researching the blood-brain barrier for creating effective treatments, as well as future directions and potential research avenues. He also discussed the topics and speakers he’s excited to see at the Blood-Brain Barrier conference this June.

View a Transcript of the Podcast here

Animal Models and Combination Therapy

Cory Abate-Shen, Ph.D., Michael and Stella Chernow Professor of Urological Oncology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

Dr. Cory Abate-Shen of Columbia University Medical Center speaks to CHI on April 8th , 2016. Dr. Abate-Shen will be presenting during the Preclinical Models in Oncology conference at the 2016 World Preclinical Congress, June 14-17 in Boston, MA.

View a Transcript of the Podcast here

Pain and the Brain: Using Patient-Derived Neurons for Preclinical Phenotypic Screening

Elizabeth D. Buttermore, Ph.D., Research Fellow, F.M. Kirby Neurobiology Center, Boston Children's Hospital; Neurobiology Department, Harvard Medical School

Elizabeth D. Buttermore of Boston Children's Hospital and Harvard Medical School speaks to CHI on March 27, 2015. Dr. Buttermore will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA.

View a Transcript of the Podcast here

Tissue Stem Cells, Tumors, Toxicity and Time

James L. Sherley, M.D., Ph.D., Director, Asymmetrex, LLC

James L. Sherley of Asymmetrex (launched in 2013 as “The Adult Stem Cell Technology Center (ASCTC)”) speaks to CHI on March 16, 2015. Dr. Sherley will be presenting during the 3D Cellular Models conference at the 2015 World Preclinical Congress, June 10-12 in Boston, MA.

Chemical Route Development of HCV Protease-Inhibitor, Telaprevir

Dr. Gerald Tanoury

Dr. Gerald Tanoury from Vertex, featured speaker at CHI's 'Efficient Process Chemistry' meeting May 22-24, 2014 in Boston, speaks about dealing with two challenging chemical steps in the scale-up of HCV protease inhibitor, Telaprevir, which was launched in 2011 as a new treatment for hepatitis C infection. Tanoury also discusses Telaprevir's route development in the context of his views on what makes an efficient route and shares with the interviewer, Dr. Anjani Shah, Conference Director for CHI, what he is interested in learning more about at the meeting.

How HIGH Can You Get? Using in vitro Data to Reduce Animal Experiments & Enabling Forms in Discovery-Development Interface

Dr. Geeti Gangal

Nandini Kashyap interviews Dr. Geeti Gangal of Novartis Institutes for Biomedical Research on March 26, 2014. Dr. Gangal will be speaking during the 2nd Annual Formulation and Drug Delivery conference which is taking place on May 21-22, 2014 as part of World Pharma Congress in Boston, MA

Development of Poorly Soluble Drug: Current and Future Perspectives on Dissolution Prediction and Experimentation

Robert A. Bellantone, Ph.D.

Nandini Kashyap interviews Dr. Robert A. Bellantone of Long Island University on February 17, 2014. Dr. Bellantone will be speaking during the 2nd Annual Formulation and Drug Delivery conference taking place May 21-22, 2014 as part of World Pharma Congress in Boston, MA

Exploring and Optimizing Cost-Effective Route toward DPP-IV Inhibitor Compounds

Nhut Diep, Ph.D.

Anjani Shah, Ph.D., Conference Director, Cambridge Healthtech Institute, interviews Dr. Nhut Diep of Forest Laboratories on February 19, 2014. Dr. Diep will be speaking during the 7th Annual 'Efficient Process Chemistry' conference taking place May 22-23, 2014 as part of CHI's World Pharma Congress May 21-23 in Boston, MA.